MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case–control study

D’Amico, Emanuele; Zanghì, Aurora; Manuti, Virginia; Allegretta, Caterina; Аморусо, А.; Serviddio, Gaetano; Avolio, Carlo

doi:10.1007/s00415-022-11391-6

Cited by 4 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Expression values in CSF were normalized using the miRNA-16 5p reference gene as endogenous control. Relative expression of miRNA 21-5p, miRNA 106a-5p, miRNA 146a-5p, and miRNA 223-3p was analyzed using the comparative Ct method (2^ -ΔΔCT ) miRNAs panel, and endogenous controls were chosen according to the literature in the field and previously published studies from our research team ( 22 , 23 ).…”

Section: Methodsmentioning

confidence: 99%

MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study

Zanghì,

Manuti,

Serviddio

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

BackgroundCirculating microRNAs (MiRNAs) have been investigated for their role in fine-tuning the adaptive immune response to inflammatory factors and in Multiple Sclerosis (MS). They have been investigated as possible biomarkers for the diagnosis and prognosis of the disease.MethodsA cross sectional study conducted at the MS centre of Foggia, Italy. We enrolled patients with (1) an age between 18 and 55 years, (2) a definitive diagnosis of relapsing remitting MS (RRMS) as per the revised McDonald criteria, and (3) naïve to any disease modifying therapy (DMTs), as well as (4) patients with other neurological disorders (OND). The aim of the study was to compare the levels of expression of miRNA 21-5p, miRNA 106a-5p, miRNA 146a-5p, and miRNA223-3p in cell-free cerebrospinal fluid (CSF) in RRMS patients and OND. Investigated MiRNAs were extracted, retrotranscribed, and then assessed by real-time polymerase chain reaction assay (q-PCR). A receiver-operator characteristic (ROC) curve was used to test MiRNAs as a biomarker for diagnosing MS. A linear regression analysis was done to find any association with disease characteristics at the time of diagnosis.ResultsA total cohort of 70 subjects (70% women) was analyzed. Out of them, 35 had a RRMS diagnosis. MiRNA 106a-5p (7.8 ± 3.8 vs 1.3 ± 0.9, p=0.03) had higher levels in RRMS patients when compared to OND. The ROC curve indicated that MiRNA 106a-5p could be considered as a disease biomarker with an area under the curve of 0.812 (p<.001; 95% CI 0.686-0.937). Linear regression analysis showed an association between the number of oligoclonal bands and MiRNA 106a-5p levels (B-coeff 2.6, p<.001; 95% CI 1.3-4.9).ConclusionWe described miRNA 106a-5p as a possible signature in the CSF of RRMS patients in early phases of the disease. Further studies are needed to characterize its role in early MS as a disease biomarker.

show abstract

Section: Methodsmentioning

confidence: 99%

MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study

Zanghì,

Manuti,

Serviddio

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, Normfinder algorithms ( 23 ) determined hsa-miR-16-5p to be the most stable endogenous normalizer. Thus, we selected it as an internal reference as previous articles used ( 24 – 27 ).…”

Section: Methodsmentioning

confidence: 99%

Heterogeneous circulating miRNA profiles of PBMAH

et al. 2022

View full text Add to dashboard Cite

ObjectivePrimary bilateral macronodular adrenal hyperplasia (PBMAH), a rare cause of Cushing syndrome, is often diagnosed as a bilateral adrenal incidentaloma with subclinical cortisol production. Circulating microRNAs (miRNAs) are a characteristic of adrenocortical adenomas, but miRNA expression in PBMAH has not been investigated. We aimed to evaluate the circulating miRNA expression in patients with PBMAH and compare them with those in patients with non-functioning adrenocortical adenoma (NFA) and cortisol-producing adrenocortical adenoma (CPA).MethodsmiRNA profiling of plasma samples from four, five, and five patients with NFA, CPA, and PBMAH, respectively, was performed. Selected miRNA expressions were validated using quantitative RT-PCR.ResultsPBMAH samples showed distinct miRNA expression signatures on hierarchical clustering while NFA and CPA samples were separately clustered. PBMAH was distinguished from the adenoma group of NFA and CPA by 135 differentially expressed miRNAs. Hsa-miR-1180-3p, hsa-miR-4732-5p, and hsa-let-7b-5p were differentially expressed between PBMAH and adenoma (P = 0.019, 0.006, and 0.003, respectively). Furthermore, PBMAH could be classified into two subtypes based on miRNA profiling: subtype 1 with a similar profile to those of adenoma and subtype 2 with a distinct profile. Hsa-miR-631, hsa-miR-513b-5p, hsa-miR-6805-5p, and hsa-miR-548av-5p/548k were differentially expressed between PBMAH subtype 2 and adenoma (P = 0.027, 0.027, 0.027, and 1.53E-04, respectively), but not between PBMAH, as a whole, and adenoma.ConclusionCirculating miRNA signature was identified specific for PBMAH. The existence of subtype-based miRNA profiles may be associated with the pathophysiological heterogeneity of PBMAH.

show abstract

“…The therapeutic choice is strictly personalized and is based on demographical, clinical, and radiological characteristics [ 19 , 20 , 21 , 22 , 23 , 24 , 25 ]. Biomarkers that can predict disability progression, monitor ongoing disease activity, and assess the treatment response are integral in making important decisions regarding MS treatment [ 26 , 27 , 28 , 29 ]. Previous studies [ 10 , 30 , 31 , 32 ] have identified fatigue as a key and prevalent symptom in MS, with a greater prevalence of approximately 80% in the primary progressive form compared with the relapsing–remitting form’s prevalence of about 60% [ 33 ].…”

Section: Introductionmentioning

confidence: 99%

Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review

Ciancio

Moretti

Natale

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

(1) Background: Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disease. Fatigue is a prevalent and debilitating symptom that significantly impacts the quality of life of these patients. A relationship between personality traits and fatigue in MS has been hypothesized but not clearly defined. (2) Methods: A literature search was carried out from databases up to April 2023 for studies correlating personality traits and fatigue in patients suffering from MS. (3) Results: A total of ten articles was included; most of the studies depict a neuroticism–fatigue correlation; however, they were not consistent in terms of the fatigue, personality, and covariate assessments. (4) Conclusions: The clinical and methodological heterogeneity of the included studies prevented us from drawing any firm conclusion on the link between personality traits and fatigue in MS. Several models of personality and different fatigue assessments have been found. Despite this, a common pathway shows that the neuroticism trait or similar personality patterns has a role in fatigue diagnosis. This may be a useful target to improve the quality of life and enhance the modification of the disease treatment results. Further homogeneous and longitudinal studies are needed.

show abstract

MicroRNAs 181a and 125a are highly expressed in naïve RRMS: a pilot case–control study

Cited by 4 publications

References 16 publications

MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study

MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study

Heterogeneous circulating miRNA profiles of PBMAH

Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review

Contact Info

Product

Resources

About